rs1045280 - ARRB2
Magnitude 2.8 · 1 study on file
Reported associations
-
Genetic association of a gain of function interferon gamma receptor 1 (IFNGR1) polymorphism and the intergenic region LNCAROD/DKK1 with Behçet's disease - Unknown journal (n.d.) · Unknown authors · PubMed 33393726
ABSTRACT: Objective: Behçet's disease is a complex systemic inflammatory vasculitis of incompletely understood etiology. We performed a large genetic study in Behçet's disease in a diverse multi-ethnic population. Methods: A total of 9,444 patients and controls from seven different populations were included in this study. Genotyping was performed using the Infinium ImmunoArray-24 V.1.0 or V.2.0 BeadChip. Analysis of expression data from stimulated monocytes, and epigenetic and chromatin interaction analyses were performed. Results: We identified two novel genetic susceptibility loci for Behçet's disease, including a risk locus in IFNGR1 (rs4896243, p value= 2.42 × 10−9; OR=1.25) and within the intergenic region LNCAROD/DKK1 (rs1660760, p value= 2.75 × 10−8; OR= 0.78). The ri
Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.
Lifestyle context
Concrete actions anchored to the cited research. We do not prescribe, we describe.
Discuss with your doctor
-
Opioid toxicity monitoring during therapy Moderate
TT genotype associated with increased adverse events from buprenorphine, fentanyl, tramadol; requires enhanced clinical surveillance
Inform prescriber of genotype; arrange more frequent monitoring for toxicity if starting opioid medications
- PharmGKB:ARRB2:TT
-
rs1045280 genotyping for methadone treatment planning Moderate
CC homozygotes show poor methadone response; genotyping identifies non-responders who may need dose escalation or alternative opioid therapy
If considering methadone for opioid dependence, discuss genotyping results with prescriber before initiation